《全国职称英语考试 卫生类B级 阅读与完形填空押题【孙、王、李三个王牌老师综合而来】》由会员分享，可在线阅读，更多相关《全国职称英语考试 卫生类B级 阅读与完形填空押题【孙、王、李三个王牌老师综合而来】（4页珍藏版）》请在金锄头文库上搜索。
1、Once daily pill could simplify HIV treatmentBeistol-Myers squibb and Gilead Sciences have combined many HIV drugs into a single pill. Sometimes the best medicine is moer than one kind of medicine. Maiaria,tuberculosis and HIV/AIDS, for example, are all treated with combinations of drugs. But that ca
2、n mean a lot of pills to take. It would be simpler if deug companies combined all the medicines into a single pill, taken just once a day .Now, two companies say they have done that foe people just starting treatment for HIV, the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gil
3、ead Sciences. They have developed a single pill that combines three drugs currently on the market . Bristol-Myers Squibb sells one of them under the name of Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.Combining drugs involeves more than technical
4、issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of HIV. In January the New England Journal of Medicine published a study of the ne
5、w pill . Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed HIV levels in more patients and with fewer side effects. Gilead paid
6、 for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the reaearch . he is paid adviser to Gilead ang Bristol-Meyers Squibb as well as the maker of Combivir, Glaxo Smith Kline. Glaxo Smith Kline reacted to the findings by saying that a single stud
7、y is of limited value. It says the effectiveness of Combivir has been shown in each of more the fifty studies.The price of the new once-daily pill has not beet announced. But Gilead ang Bristol-Myers Squibb say they will provide it at reduced cost to developing countries. They plan in the next few m
8、onths to ask the United States Food and Drug Administration to approve the new pill. There are limits to who could take it because of the different drugs it contains.For example pregnant women are told not to take Sustiva because of the risk of birth disorders.Experts say more than forty million peo
9、ple around the world are living with HIV.Once daily pill could simplify HIV treatmentBeistol-Myers squibb and Gilead Sciences have combined many HIV drugs into a single pill. Sometimes the best medicine is moer than one kind of medicine. Maiaria,tuberculosis and HIV/AIDS, for example, are all treate
10、d with combinations of drugs. But that can mean a lot of pills to take. It would be simpler if deug companies combined all the medicines into a single pill, taken just once a day .Now, two companies say they have done that foe people just starting treatment for HIV, the virus that causes AIDS. The c
11、ompanies are Bristol-Myers Squibb and Gilead Sciences. They have developed a single pill that combines three drugs currently on the market . Bristol-Myers Squibb sells one of them under the name of Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.Combi
12、ning drugs involeves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of HIV. In January the New England Journa
13、l of Medicine published a study of the new pill . Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed HIV levels in more patients
14、 and with fewer side effects. Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the reaearch . he is paid adviser to Gilead ang Bristol-Meyers Squibb as well as the maker of Combivir, Glaxo Smith Kline. Glaxo Smith Kline reacted to
15、the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more the fifty studies.The price of the new once-daily pill has not beet announced. But Gilead ang Bristol-Myers Squibb say they will provide it at reduced cost to developi
16、ng countries. They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill. There are limits to who could take it because of the different drugs it contains.For example pregnant women are told not to take Sustiva because of the risk of birth disorders.Experts say more than forty million people around the world are living with HIV.Once daily pill could simplify HIV treatmentBeistol-Myers squibb and Gil
